AbbVie Inc. closed $6.48 below its 52-week high ($199.95), which the company reached on September 3rd.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...

Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer, was the key asset in AbbVie's $10.1 billion acquisition of biotech ImmunoGen that ...

Plus, news about Vigil Neuroscience, AC Immune and Athira Pharma: Capricor Therapeutics, Nippon Shinyaku expand commercial pact into Europe: The new deal builds off an existing partnership for a ...

Collaboration to leverage AbbVie's eye care expertise and Ripple's innovative drug delivery platform to develop next-generation sustained release drug delivery implants for the treatment of glaucoma ...

This event contributes to the high level of graduate employability in DCU as highlighted in our latest Graduate Outcome Survey results from this year, which indicates that 94% of DCU students are in ...

NFL Week 3 power rankings: Saints and Buccaneers skyrocket, Cowboys and Ravens fall September harvest moon will provide ...

Given its better valuation, we believe that Pfizer stock (NYSE: PFE) is currently a better pick than its industry peer – AbbVie stock (NYSE:ABBV). PFE stock trades at a much lower multiple of 11x ...